Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Improving manufacturing of CAR-T cells in multiple myeloma: PHE885 & other novel constructs

In this video, Andrew Cowan, MD, Fred Hutchinson Cancer Center, Seattle, WA, briefly discusses the importance of improving the manufacturing of BCMA-directed CAR-T cells in multiple myeloma, and further highlights the promising preliminary results observed with the use of PHE885. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consulting: BMS, Adaptive
Research funding: BMS, Janssen, Adaptive, Harpoon, AbbVie, Sanofi, Nektar